CEREZYME
Drug
Genzyme Corporation
Total Payments
$4.2M
Transactions
3,202
Doctors
1,518
Companies
5
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $971,635 | 523 | 268 |
| 2023 | $1.5M | 450 | 212 |
| 2022 | $71,953 | 126 | 90 |
| 2021 | $56,950 | 102 | 87 |
| 2020 | $82,482 | 100 | 59 |
| 2019 | $108,094 | 255 | 184 |
| 2018 | $844,723 | 1,182 | 639 |
| 2017 | $522,733 | 464 | 192 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.5M | 354 | 60.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $976,153 | 300 | 23.4% |
| Travel and Lodging | $317,825 | 505 | 7.6% |
| Consulting Fee | $191,384 | 63 | 4.6% |
| Food and Beverage | $111,164 | 1,954 | 2.7% |
| Space rental or facility fees (teaching hospital only) | $65,550 | 26 | 1.6% |
Payments by Type
Research
$2.5M
354 transactions
General
$1.7M
2,848 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| ESC - Evaluating functional relevance of Apoe in Microglia and Astrocytes in mediating Gaucher Neuronopathy | GENZYME CORPORATION | $868,886 | 0 |
| Gaucher Disease Registry Protocol | SANOFI US SERVICES INC. | $619,064 | 0 |
| ESC - CONSTRUCTING THE BRAIN CELL ATLAS OF GAUCHER DISEASE, CONTRIBUTION OF DIFFERENT CELL TYPE TO NEURODEGENERATION AND NEUROINFLMMATION AND IMPACT OF SRT IN REVERSAL OF DISEASE PATHWAYS | GENZYME CORPORATION | $566,365 | 0 |
| Gaucher Generation - Cognition, Motor Control, Imaging and Pathologic Biomarkers in GBA1 Mutation Carriers | GENZYME CORPORATION | $146,326 | 0 |
| Gaucher Generation 2012 Winner: Studies to Delineate Specific Phenotypes of Gaucher disease and decipher respective biomarker signatures and genetic underpinnings | GENZYME CORPORATION | $120,000 | 0 |
| Q1 2018 Gaucher LSD Registry | GENZYME CORPORATION | $41,043 | 0 |
| Q4 2017 Gaucher LSD Registry | GENZYME CORPORATION | $36,954 | 0 |
| Pilot study to assess immune biomarkers and growth factors related to bone pathology in pediatric patients with Gaucher disease. | GENZYME CORPORATION | $29,095 | 0 |
| Gaucher Disease Registry | GENZYME CORPORATION | $22,324 | 0 |
| Prevalence of Gaucher Among Patients with osteopenia/osteoporosis | GENZYME CORPORATION | $13,982 | 0 |
| International Collaborative Gaucher Group (ICGG) Gaucher Registry | GENZYME CORPORATION | $12,734 | 3 |
| GAUCHER REGISTRY | GENZYME CORPORATION | $12,326 | 4 |
| Gaucher Disease Registry Protocol | GENZYME CORPORATION | $4,500 | 3 |
| ICGG Gaucher Registry | GENZYME CORPORATION | $3,585 | 1 |
| Investigating the psychosocial needs and health related quality of life in patients using substrate reduction therapy to treat non-neuropathic Gaucher disease | GENZYME CORPORATION | $3,450 | 0 |
| Q1 2017 Gaucher LSD Registry | GENZYME CORPORATION | $1,150 | 0 |
| Sanchez-Valle_61198078_Rare Disease Registry | GENZYME CORPORATION | $378.75 | 0 |
| International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry | GENZYME CORPORATION | $320.00 | 1 |
| Genzyme Rare Disease Registry | GENZYME CORPORATION | $300.00 | 0 |
| Sanchez-Valle_61198078-Rare Disease Registry | GENZYME CORPORATION | $138.75 | 0 |
Top Doctors Receiving Payments for CEREZYME — Page 61
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , D.O | Internal Medicine | Lumberton, NC | $11.29 | 1 |
| , M.D | Pediatrics | Manassas, VA | $11.27 | 1 |
| , APRN | Family | Fayetteville, AR | $11.26 | 1 |
| , M.D | Hematology & Oncology | Jonesboro, AR | $11.22 | 1 |
| , MD | Medical Oncology | Jonesboro, AR | $11.22 | 1 |
| , M.D | Hematology & Oncology | Rockville, MD | $11.12 | 1 |
| , M.D | Hematology & Oncology | Germantown, TN | $11.00 | 1 |
| , MD | Hematology & Oncology | Niles, IL | $10.94 | 1 |
| , MD | Hematology & Oncology | Niles, IL | $10.94 | 1 |
| , MD | Hematology & Oncology | Niles, IL | $10.94 | 1 |
| Chul So Moon | — | East Stroudsburg, PA | $10.93 | 1 |
| , MD | Hospice and Palliative Medicine | Niagara Falls, NY | $10.93 | 1 |
| , M.D | Family Medicine | Chester, MT | $10.86 | 1 |
| , MD | Hematology & Oncology | Memphis, TN | $10.49 | 1 |
| , M.D | Hematology & Oncology | Memphis, TN | $10.49 | 1 |
| , M.D | Hematology & Oncology | Fort Smith, AR | $10.39 | 1 |
| , MD | Hematology & Oncology | Easton, PA | $9.99 | 1 |
| , M.D | Medical Oncology | Sun City, AZ | $9.61 | 1 |
| , M.D | Medical Oncology | Ft Walton Beach, FL | $7.73 | 1 |
Ad
Manufacturing Companies
- GENZYME CORPORATION $3.2M
- SANOFI US SERVICES INC. $619,064
- Genzyme Corporation $266,287
- SANOFI-AVENTIS U.S. LLC $88,605
- BIOVERATIV THERAPEUTICS INC. $27,736
Product Information
- Type Drug
- Total Payments $4.2M
- Total Doctors 1,518
- Transactions 3,202
About CEREZYME
CEREZYME is a drug associated with $4.2M in payments to 1,518 healthcare providers, recorded across 3,202 transactions in the CMS Open Payments database. The primary manufacturer is Genzyme Corporation.
Payment data is available from 2017 to 2024. In 2024, $971,635 was paid across 523 transactions to 268 doctors.
The most common payment nature for CEREZYME is "Unspecified" ($2.5M, 60.1% of total).
CEREZYME is associated with 20 research studies, including "ESC - Evaluating functional relevance of Apoe in Microglia and Astrocytes in mediating Gaucher Neuronopathy" ($868,886).